Sandoz continues women leadership program to build talent pipeline

Holzkirchen, Germany, September 26, 2014 – For the fourth consecutive year, Sandoz held the global Women@Sandoz leadership program for top women associates. Eighteen women, representing all Sandoz regions and functions, participated in the three-day event, sponsored by Sandoz Global Head, Richard Francis.

 

“We are focused on achieving and maintaining a strong gender balance at all levels, in every area of our business, because we believe diversity is good for business and inclusion is good for our people,” said Lisa Richert, Sandoz Chair of the Global …

/by

Sandoz launches Kerdyn TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, September 22, 2014 – Sandoz, through its branded dermatology business, PharmaDerm, today announced the US launch of KERYDINTM (tavaborole) topical solution, 5%, developed  by Anacor Pharmaceuticals, Inc.

In July 2014, Sandoz announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize KERYDINTM in the US.

KERYDINTM is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, a fungal infection of the …

/by

Generic medicines saved US healthcare system nearly USD 240 billion in 2013

September 18, 2014 – The use of generic medicines saved US patients and payors a total of USD 239 billion in 2013 – an increase of 14% over 2012 and more than in any previous year.

That was the main finding of a new study by the IMS Institute for Healthcare Informatics, commissioned by the US Generic Pharmaceutical Association (GPhA).

The latest study, details of which have just been released by GPhA, showed that the use of generics in the US saved a total of …

/by

Dealing with the spread of chronic disease in Africa

September 10, 2014 – Sub-Saharan Africa is facing a healthcare tipping point. Policy and resources are mainly dedicated to fighting infectious diseases today. HIV, malaria and tuberculosis are the big targets. But over the next 15 years chronic diseases like cancer, heart disease, and kidney failure will become the major killers. By 2030 they will account for 42% of all deaths in the region, up from 25% today, says the World Health Organization.

 

Their rise may be inevitable, but their impact could be better managed. Education, policy and health investment can …

/by

Sandoz Regional BioCamp winner finishes among top three in Basel

Basel, September 2, 2014 – Janko Ignjatovic of Serbia has been selected as one of three individual winners of the Novartis International BioCamp held in Basel last week. Mr. Ignjatovic, who studies pharmacy at the University of Belgrade, came to the event through the Regional BioCamp, which took place in June and was organized by Lek, a Sandoz company.

 

Mr. Ignjatovic proved to be the best at combining a scientific and business solution in his case study at the Regional BioCamp in Slovenia, which is what promoted him to participate in the Novartis BioCamp. …

/by

Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 29, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.
Read more.

/by

Novartis releases 2013 Corporate Responsibility Performance Report

August 29, 2014 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.

For 2013, we have consolidated information previously published in our separate GRI; Health, Safety and Environment; and United Nations Global Compact reports into a single Corporate Responsibility Performance Report.

This report enhances our transparency in several key …

/by

Sandoz Brazil introduces a new option for oncology patients

  • First generic version of oncology medicine bortezomibe in Brazil
  • New therapeutic option for patients suffering from multiple myeloma

São Paulo, August 26, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.

Sandoz will distribute and promote bortezomibe in Brazil, based on an agreement with Accord Pharmaceuticals. This will be the first Sandoz medicine marketed in Brazil for treatment of hematologic – as opposed to …

/by

Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 21, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.

Rheumatic heart disease (RHD) has been practically eradicated in wealthy nations, but in the developing world the disease remains a major cause of morbidity and mortality, particularly in children …

/by

Sandoz receives first aproval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

  • Mexico’s Health Authority (COFEPRIS) grants marketing authorization for Airflusal® Forspiro®
  • Approval for 50-100mg, 50-250mg and 50-500mg dosage forms
  • Product to be branded IrFlosolTM Forspiro® in Mexico
  • Airflusal® Forspiro® already launched in four European countries as well as in South Korea

Holzkirchen, August 20, 2014 – Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic …

/by